IDiyas

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Albert Kudzovi Amegadzie

USPTO Granted Patents = 31 


 

Average Co-Inventor Count = 9.1

ph-index = 8

Forward Citations = 245(Granted Patents)


Location History:

  • Indianapolis, IN (US) (2007 - 2011)
  • Moorpark, CA (US) (2009 - 2023)
  • Westlake Village, CA (US) (2024)

Company Filing History:

goldMedal25 out of 1,970 
 
Amgen Inc.
 patents
silverMedal6 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 2007-2025

where 'Filed Patents' based on already Granted Patents

31 patents (USPTO):
1. 12473289 - Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use (2025-11-18),
2. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),
3. 12421234 - Solid state forms (2025-09-23),
4. 12415806 - Solid state forms (2025-09-16),
5. 12398133 - Solid state forms (2025-08-26),
6. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),
7. 11827635 - Solid state forms (2023-11-28),
8. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),
9. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),
10. 11236091 - Solid state forms (2022-02-01),
11. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),
12. 11045484 - KRAS G12C inhibitors and methods of using the same (2021-06-29),
13. 10889581 - Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use (2021-01-12),
14. 10246429 - Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2019-04-02),
15. 9663476 - Glycine transporter-1 inhibitors (2017-05-30),

Certainly! Below is the article about inventor Albert Kudzovi Amegadzie based on the information provided:

Title: Innovator Spotlight: Albert Kudzovi Amegadzie - Pioneering Cancer Treatments

Introduction:

Albert Kudzovi Amegadzie, a prolific inventor in the field of oncology, hails from Indianapolis, IN. With a remarkable portfolio of 24 patents, his groundbreaking work is transforming the landscape of cancer treatment.

Latest Patents:

1. KRAS G12C inhibitors and methods of using the same: Amegadzie's innovative inhibitors target KRAS G12C mutations, offering promising treatment options for pancreatic, colorectal, and lung cancers.

2. Substituted piperazines as KRAS G12C inhibitors: Another key patent by Amegadzie, focusing on novel compositions and methods for combating various cancer types.

Career Highlights:

Amegadzie is associated with Eli Lilly and Company, a pioneering pharmaceutical firm at the forefront of developing life-saving medications. His contributions have significantly advanced the field of cancer research and therapy.

Collaborations:

Among his esteemed colleagues are Wenyuan Qian and Vu Van Ma, with whom Amegadzie collaborates closely to drive innovation and synergies in developing cutting-edge treatments for cancer patients.

Conclusion:

In conclusion, Albert Kudzovi Amegadzie's dedication and ingenuity in inventing novel cancer therapies underscore his commitment to improving patient outcomes in the fight against cancer. His prolific patents and collaborations exemplify his significant impact on the field of oncology.

Would you like to explore more inventors or patents in the field of oncology or any other specific area?

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…